Biodegradable-polymer stents versus durable-polymer stents

Affiliations

¹ Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA 02115, USA. Electronic address: wei@hsph.harvard.edu.
² Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA 02115, USA.
³ New England GRECC, VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Comment

Lee-Jen Wei et al. Lancet. 2019.

. 2019 May 11;393(10184):1932-1933.

doi: 10.1016/S0140-6736(19)30023-6.

¹ Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA 02115, USA. Electronic address: wei@hsph.harvard.edu.
² Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA 02115, USA.
³ New England GRECC, VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

No abstract available

Comment on

Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Muller O, Moarof I, Siontis GCM, Cook S, Weilenmann D, Kaiser C, Cuculi F, Hunziker L, Eberli FR, Jüni P, Windecker S. Pilgrim T, et al. Lancet. 2018 Sep 1;392(10149):737-746. doi: 10.1016/S0140-6736(18)31715-X. Epub 2018 Aug 28. Lancet. 2018. PMID: 30170848 Clinical Trial.